| Literature DB >> 33838022 |
Masakazu Saitoh1,2, Yuta Takahashi3,4, Daisuke Okamura4, Mitsutoshi Akiho5, Hidetoshi Suzuki5, Naoki Noguchi6, Yukito Yamaguchi6, Kentaro Hori2, Yuichi Adachi2, Tetsuya Takahashi1.
Abstract
AIMS: Functional decline is associated with worse outcomes in patients with elderly heart failure (HF), but little is known about the prognostic impact of hospital-acquired disability (HAD) during hospital stay after acute HF. The present study examines the prognostic significance of HAD in the prediction of all-cause mortality in elderly patients who admitted for acute HF. METHODS ANDEntities:
Keywords: Elderly; Heart failure; Hospital-acquired disability; Prognosis
Mesh:
Year: 2021 PMID: 33838022 PMCID: PMC8120367 DOI: 10.1002/ehf2.13356
Source DB: PubMed Journal: ESC Heart Fail ISSN: 2055-5822
Baseline characteristics
| Total ( | HAD ( | Non‐HAD ( |
| ||||
|---|---|---|---|---|---|---|---|
| Age (years) | 81 | (75, 86) | 83 | (78, 88) | 81 | (75, 86) | <0.001 |
| Female, | 916 | (47) | 237 | (50) | 679 | (46) | 0.125 |
| BMI (kg/m2) | 22.3 | (20.0, 25.0) | 21.9 | (19.6, 24.6) | 22.4 | (20.2, 25.0) | 0.018 |
| Aetiology, | 0.391 | ||||||
| Ischaemic | 638 | (33) | 166 | (35) | 472 | (32) | |
| HHD | 192 | (10) | 50 | (11) | 142 | (10) | |
| Valvular | 602 | (31) | 148 | (31) | 454 | (31) | |
| Myopathy | 202 | (10) | 37 | (8) | 165 | (11) | |
| Others | 307 | (16) | 73 | (15) | 234 | (16) | |
| NYHA class ≥III, | 1342 | (69) | 353 | (74) | 989 | (68) | 0.006 |
| sBP (mmHg) | 136 | (114, 160) | 138 | (114, 160) | 136 | (115, 160) | 0.517 |
| CS, | 0.264 | ||||||
| 1 | 920 | (47) | 237 | (50) | 683 | (47) | |
| 2 | 832 | (43) | 189 | (40) | 643 | (44) | |
| 3 | 188 | (10) | 50 | (10) | 138 | (9) | |
| LVEF | 44 | (30, 59) | 45 | (31, 58) | 43 | (30, 59) | 0.961 |
| HF class, | 0.711 | ||||||
| HFrEF | 826 | (43) | 196 | (41) | 630 | (43) | |
| HFmrEF | 297 | (15) | 79 | (17) | 218 | (15) | |
| HFpEF | 818 | (42) | 201 | (42) | 617 | (42) | |
| LAD (mm) | 43 | (39, 47) | 43 | (37, 47) | 43 | (39, 48) | 0.278 |
| E/A | 1.20 | (0.77, 1.86) | 1.30 | (0.83, 1.90) | 1.10 | (0.75, 1.86) | 0.196 |
| E/e' | 21.5 | (16.1, 29.6) | 23.2 | (16.5, 30.4) | 21.0 | (16.0, 29.2) | 0.153 |
| Hypertension, | 1,257 | (65) | 311 | (65) | 946 | (65) | 0.783 |
| Dyslipidaemia, | 582 | (30) | 148 | (31) | 434 | (30) | 0.565 |
| Diabetes mellitus, | 591 | (30) | 134 | (28) | 457 | (31) | 0.229 |
| CKD, | 572 | (29) | 143 | (30) | 429 | (29) | 0.772 |
| COPD, | 157 | (8) | 40 | (8) | 117 | (8) | 0.771 |
| CVD, | 270 | (14) | 72 | (15) | 198 | (14) | 0.402 |
| Current smoking, | 247 | (13) | 70 | (15) | 177 | (12) | 0.133 |
| Alb (g/dL) | 3.6 | (3.2, 3.9) | 3.5 | (3.1, 3.8) | 3.6 | (3.3, 3.9) | 0.001 |
| GNRI | 95 | (88, 103) | 93 | (85, 100) | 96 | (89, 103) | <0.001 |
| Hb (g/dL) | 11.5 | (10.0, 12.9) | 11.2 | (9.9, 12.7) | 11.6 | (10.1, 13.0) | 0.063 |
| BUN (g/dL) | 24.2 | (18.1, 33.9) | 25.7 | (18.4, 37.3) | 23.6 | (18.0, 32.7) | 0.003 |
| sCr (mg/dL) | 1.12 | (0.86, 1.57) | 1.15 | (0.84, 1.72) | 1.12 | (0.86, 1.52) | 0.179 |
| BNP (pg/dL) | 663 | (351, 1145) | 681 | (327, 1330) | 652 | (360, 1070) | 0.185 |
| NT‐pro BNP (pg/dL) | 4622 | (2431, 9342) | 6,276 | (2681, 15 565) | 4,219 | (2319, 8655) | <0.001 |
| CRP (mg/dL) | 0.62 | (0.19, 2.04) | 0.91 | (0.25, 3.02) | 0.50 | (0.17, 1.66) | <0.001 |
| MAGGIC risk score, point | 27 | (23–31) | 28 | (24‐32) | 27 | (23‐31) | <0.001 |
| Early ambulation, | 966 | (50) | 161 | (34) | 805 | (55) | <0.001 |
| ADLs before admission, point | 100 | (85, 100) | 95 | (85, 100) | 100 | (90, 100) | <0.001 |
| ADLs at hospital discharge, point | 95 | (80, 100) | 80 | (50, 90) | 100 | (90, 100) | <0.001 |
| Gait speed, m/s at hospital discharge | 0.76 | (0.56, 0.95) | 0.56 | (0.43, 0.74) | 0.80 | (0.50, 0.97) | <0.001 |
| SPPB score, point at hospital discharge | 9 | (6, 11) | 6 | (3, 8) | 10 | (7, 12) | <0.001 |
| ACEI/ARB, | 812 | (42) | 174 | (37) | 638 | (44) | 0.026 |
| Beta‐blocker, | 1195 | (62) | 263 | (55) | 932 | (64) | 0.015 |
| Diuretics, | 1643 | (85) | 388 | (82) | 1,255 | (86) | 0.074 |
| Place of residence, | 0.267 | ||||||
| Home | 1814 | (93) | 444 | (93) | 1,370 | (94) | |
| Nursing care | 108 | (6) | 30 | (6) | 78 | (5) | |
| Other hospital | 19 | (1) | 2 | (1) | 17 | (1) | |
| Living alone, | 409 | (21) | 117 | (25) | 292 | (20) | 0.305 |
| Return to home, | 1671 | (86) | 326 | (68) | 1345 | (92) | <0.001 |
| Hospital stay (days) | 16 | (11, 24) | 18 | (12, 29) | 16 | (11, 22) | <0.001 |
Data are median (interquartile range).
A, late (atrial) diastolic transmitral flow velocity; ACEI, angiotensin‐converting enzyme inhibitor; ADLs, activities of daily living; Alb, albumin; ARB, angiotensin II receptor block; BMI, body mass index; BNP, brain natriuretic peptide; BNU, blood urea nitrogen; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRP, C‐reactive protein; CS, clinical scenario; CVD, cerebrovascular disease; E, early diastolic transmitral flow velocity; e', early diastolic mitral annular velocity; GNRI, geriatric nutritional risk index; Hb, haemoglobin; HF, heart failure; HFmrEF, heart failure with mid‐range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; NT‐pro BNP, N‐terminal pro‐brain natriuretic peptide; NYHA, New York Heart Association; sBP, systolic blood pressure; sCr, serum creatinine; SPPB, short physical performance battery.
Figure 1(A) Kaplan–Meier curve showing all‐cause death among elderly patients with HF with and without hospital‐acquired disability. (B) Kaplan–Meier curve showing HF readmission among elderly patients with HF with and without hospital‐acquired disability. HF, heart failure.
The prognostic impact of addition of HAD to MAGGIC risk score in Cox regression analyses
| Predictor | All‐cause death | HF readmission | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI |
| HR | 95% CI |
| |
| Risk score | ||||||
| HAD | ||||||
| Linear (every 5‐point BI score decline) | 1.019 | 1.014–1.024 | <0.001 | 1.004 | 0.998–1.009 | 0.193 |
| Dichotomized (HAD vs. no HAD) | 1.887 | 1.546–2.305 | <0.001 | 1.203 | 1.022–1.416 | 0.027 |
| 3‐category | ||||||
| No HAD | 1 | 1 | ||||
| Mild HAD | 1.551 | 1.229–1.957 | <0.001 | 1.151 | 0.935–1.418 | 0.185 |
| Sever HD | 2.243 | 1.768–2.847 | <0.001 | 1.289 | 1.029–1.616 | 0.027 |
| MAGGIC risk score | ||||||
| Linear (every 1‐point decrease) | 1.051 | 1.035–1.066 | <0.001 | 1.018 | 1.006–1.030 | 0.003 |
| Combination of HAD and MAGGIC risk score | ||||||
| Model1 | ||||||
| HAD linear | 1.016 | 10.11–1.021 | <0.001 | 1.003 | 0.997–1.008 | 0.304 |
| MAGGIC risk score | 1.061 | 1.047–1.076 | <0.001 | 1.024 | 1.012–1.035 | <0.001 |
| Model 2 | ||||||
| HAD dichotomized | 1.772 | 1.450–2.167 | <0.001 | 1.193 | 1.005–1.416 | 0.043 |
| MAGGIC risk score | 1.051 | 1.035–1.066 | <0.001 | 1.016 | 1.004–1.028 | 0.009 |
| Model 3 | ||||||
| 3‐category | ||||||
| No HAD | 1 | 1 | ||||
| Mild HAD | 1.515 | 1.200–1.914 | 0.001 | 1.118 | 0.908–1.378 | 0.294 |
| Sever HAD | 1.964 | 1.546–2.496 | <0.001 | 1.227 | 0.978–1.540 | 0.077 |
| MAGGIC risk score | 1.058 | 1.044–1.073 | <0.001 | 1.023 | 1.011–1.034 | 1.023 |
CI, confidence interval; HAD, hospital‐acquired disability; HR, hazard ratio; MAGGIC, the Meta‐analysis Global Group in Chronic Heart Failure